Chapters authored
Urinary Tract Infections in Neuro-Patients
The majority of neurological diseases may have an impact on lower urinary tract function. High intravesical pressure, post-void residual and incontinence are the main consequences of this dysfunction. All the mentioned conditions are inductive factors for urinary tract infections (UTIs). In addition, the potential complications of neurogenic urinary disorders (reflux, stone formation, incomplete emptying of the bladder), and the methods of urine drainage (intermittent or indwelling catheters, urinary diversion) contribute even more to UTIs. In neuro-patients, all UTIs are considered as complicated ones and there is a different microbiology as compared to the general population. In this chapter, inductive factors for UTIs in neuro-patients will be analyzed and the potential solutions will be exposed. There is a special mention in asymptomatic bacteriuria, which is correlated to neurogenic urinary dysfunction and it is clinically total different from UTI. Asymptomatic bacteriuria should not be treated as the treatment has a negative final outcome for the patient.
Part of the book: Microbiology of Urinary Tract Infections
Lower Urinary Tract Symptoms (LUTS) and Sexual Function and Dysfunction
In recent years, the coexistence of sexual dysfunction (SD) and lower urinary tract symptoms (LUTS) has become a popular topic for researchers. Numerous clinical epidemiologic studies have been planned for this reason and have evaluated the relationship between these seemingly irrelevant urological conditions. The connection between SD and LUTS has already been acknowledged, and common pathophysiological pathways have been recognized. In this chapter was attempted to evaluate the impact on patient’s quality of life (QoL), common pathophysiological pathways and therapy aspects of this condition. SD and LUTS are common problems among the general population and affect a great percentage of urological patients. It is a subject that affects the community in social, financial, and psychological terms. In this case, research for new treatment options has been triggered as phosphodiesterase type 5 inhibitors established their role as the widely approved combination therapy.
Part of the book: Lower Urinary Tract Dysfunction